精神分裂症信使RNA疗法的开发
研究以人群遗传学关联定义精神分裂症候选靶点,通过家系研究临床验证GRIA3截短变异与重性精神病的X连锁遗传,并在患者神经元中纠正变异恢复GRIA3表达;据此开发GRIA3 mRNA药物,小鼠实验显示耐受良好、脑内广泛表达GluA3并挽救MK-801诱导的精神病模型行为异常。
要点
- GRIA3罕见蛋白截短变异与重性精神病呈X连锁遗传。
- 纠正患者神经元GRIA3变异可恢复GRIA3表达。
- GRIA3 mRNA药物在小鼠中耐受良好并挽救MK-801模型行为异常。
核心结论
- 值得进一步开发GRIA3 mRNA药物走向临床评估以治疗精神分裂症。
研究设计与样本
- 候选药物靶点定义为人群研究关联精神分裂症的基因,并通过家系研究进行临床验证。
- 在30,813例美国医疗系统患者中识别精神分裂症风险基因罕见蛋白截短变异携带者。
- 对一名验证靶点开发mRNA药物并开展临床前研究。
主要发现
- 家系中发现GRIA3罕见蛋白截短变异与重性精神病之间呈X连锁遗传模式。
- 在受累男性家系成员神经元中纠正该截短变异可恢复GRIA3表达。
- GRIA3 mRNA药物在小鼠中耐受良好,实现GluA3脑内广泛表达,并挽救MK-801药理学诱导精神病模型的行为异常。
临床怎么用
- 为精神分裂症药物开发提供从人群遗传关联到家系验证再到mRNA药物的转化路径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few gene-disease associations identified by human genetic studies lead to new drugs that advance to first-in-human trials. Schizophrenia exemplifies this translational gap: thousands of gene-disease associations have been reported, but antipsychotics act via mechanisms introduced in the 1950s. To close the gap, clinical research strategies are needed that generalize across genes and diseases. METHODS: Candidate drug targets were defined as genes linked to schizophrenia by population-based studies. Clinical validation of candidate targets was performed through family-based studies. The molecular effects of clinically validated targets were confirmed by correcting mutations in the neurons from affected family members. For one validated target, a messenger RNA (mRNA) drug was developed, and pre-clinical studies of the drug were performed. RESULTS: Carriers of rare protein-truncating variants (PTVs) in schizophrenia risk genes were identified in 30,813 patients of a US healthcare system. These included two female relatives with a rare PTV in GRIA3, which encodes the GluA3 subunit of the AMPA-type glutamate receptor. Further investigation of the family found an X-linked pattern of inheritance between the PTV and severe mental illness. Correction of the PTV in neurons of affected male family members restored GRIA3 expression. A GRIA3 mRNA drug was developed and in mice was well tolerated, resulted in broad brain expression of GluA3, and rescued behavioral abnormalities in a pharmacologically induced psychosis model (MK-801). CONCLUSIONS: Further development toward clinical evaluation of a novel GRIA3 mRNA drug to treat schizophrenia is warranted.
引用
- Simons NW, Patel V, Li H, et al. Development of a messenger RNA therapy for schizophrenia. Biol Psychiatry. 2026. PMID: 42863781. doi:10.1016/j.biopsych.2026.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。